Track medtech innovations from your desktop, subscribe to Innovation Hub.

Learn More
innovation hub

Q1 2020 Emerging Medtech Spotlight

Next Digital Event: Friday, April 24

Purchase Access Apply to present Free Trial

Access Includes

  • 10 minute streaming CEO Presentation for each company (audio and slides)
  • Downloadable Executive Summary (PDF) for each company
  • Stage of development, fundraising and strategic partnering overview for each company
  • Event notebook with Executive Summaries for all companies
  • Virtual networking/partnering tool to request additional information and meetings with companies
  • Ability to replay presentations post-event

Sample Profile

nView medical

Next generation medical imaging technology to enable minimally invasive surgical procedures
Key Executive
nView medical

Cristian Atria
Founder & CEO


City: Salt Lake City

State: UT

Country: United States

Company Type:

Year Established: 2012

Additional Details: The company has received $2.8M non-dilutive funding from NSF, NIH, UTAH and $2.6M from investors with seed round led by Fusion Fund. The company has lined up customers with champions in top 10 pediatric hospitals, 2 IRBs in process and pilots planned in 1H 2020. Core patents are issued with 3 in process.

Company Details
Company Status

Financing Status: Currently raising money

Financial Round: Series A

Seeking: $8M

Regulatory/Development Status: FDA 510(k) Cleared. Broad indication in adult and pediatrics.

Revenue (Past Year): Private

Sales Projection (5 Years from Now): $22M in 2022

Additional details: nView medical is a surgical company with breakthrough technology. Its first product, nView s1, is FDA cleared with four patents issued or filed. By leveraging AI and GPU/cloud computing nView s1 provides 3D images faster, with less radiation. Pilots are expected in 1H 2020. nView is seeking an $8M series-A raise in 1H 2020. The company strategy is to win in the pediatric beachhead before expanding into the adult market with offerings in imaging, navigation and robotics. nView targets an exit to strategics, with its closest comparable being Mobius imaging and Cardan robotics sold to Stryker in 2019 for $500M.